The piloting of online platforms to support networks providing complementary information is an example of the agency striving to enhance the cohesion of the networks, the collection and presentation of data, and the interaction between the networks and the agency. [...] This is explained by the fact that during the preparation in 2021 of the above-mentioned roadmap, the agency anticipated the potential implications of a new regulation, based on the recommendations formulated further to the fourth external evaluation of the EMCDDA that was carried out by the Commission in 2018. [...] Ensure timely and high-quality and of serious adverse events, and the related public health, safety and security Union and its Member implementation of the risk assessment components of the EWS, to increase the responsiveness of the system and the 4. [...] Implementation of comprehensive, holistic system: improve quality and coverage in needs emerging from the new EU drugs policy framework (the EU security union the EMCDDA/EUDA and up-to-date the implementation of supply and supply strategy 2020-2025 and the EU drugs strategy and action plan on drugs 2021-2025) monitoring system understanding of the reduction indicators in the Member and the securit. [...] Implementation support the implementation by the NFPs framework for the collaboration between the agency and the NFPs, in close and management of Strengthen the of the RDF collaboration with the Reitox network (2024-2026), while the RDF runs in parallel the Reitox grant European Drug until 2025 agreements Information System B2.2.
Authors
Related Organizations
- Pages
- 138
- Published in
- Portugal
Table of Contents
- Foreword by the EMCDDA Director 5
- Mission statement 7
- Mission 7
- Vision 7
- Values 8
- Responding to European Union needs in 2024-2026 9
- Introduction 9
- The role of the EMCDDA/EUDA 9
- Organisational transformation 10
- Ensuring quality and core services during the transition period 10
- Developments that will shape our work 10
- Greater diversity in drug availability and use is creating new health and policy challenges 10
- New psychoactive substances: a growing public health concern 11
- Drug markets: a key threat to the security of the European Union 12
- Impact of war and geopolitical instability 12
- International developments influencing the EU drug situation and responses 13
- Cannabis policies becoming increasingly complex 13
- The EU drug monitoring system must continuously evolve 14
- EU drug policy context 15
- Key institutional developments with an impact on the EMCDDA’s/EUDA’s future activities 17
- Other relevant developments 17
- Resources 18
- II.1. Multiannual work programme 2024-2026 19
- II.1.1. Introduction – the EMCDDA’s/EUDA’s strategic approach 19
- Organisational transformation driven by a ‘customer-first’ approach 21
- Overarching commitments 22
- II.1.2. Strategic objectives, actions and expected results 2024-2026 23
- II.2. Human and financial resources outlook for 2024-2026 36
- II.2.1. Overview of the past and current situation 36
- II.2.2. Outlook for 2024-2026 36
- New tasks 36
- Growth of existing tasks and additional tasks 37
- II.2.3. Programming resources for 2024-2026 37
- Financial resources 37
- Human resources 38
- II.2.4. Strategy for achieving efficiency gains 38
- II.2.5. Negative priorities / decrease in existing tasks 39
- III.1. Executive summary 40
- III.2. Activities 41
- III.2.1. Main area 1: Health 41
- Overview 41
- MONITORING 41
- PREPAREDNESS 43
- The EU Early Warning System and risk assessment of new psychoactive substances (16F ) 43
- European Drug Alert System (EDAS) 45
- Preparedness – Laboratories Network (PLANET) 46
- Threat assessment 47
- COMPETENCE DEVELOPMENT 48
- Practice support 48
- Policy support 50
- III.2.2. Main area 2: Security 62
- Overview 62
- MONITORING 62
- PREPAREDNESS 63
- COMPETENCE DEVELOPMENT 65
- III.2.3. Main area 3: Business drivers 72
- Business driver 1: Institutional 72
- OVERVIEW 72
- Focus on smooth transition and successful launch of the EUDA 72
- Corporate communication 72
- Business driver 2: Partnership 75
- OVERVIEW 75
- Business driver 3: Scientific capacity 79
- OVERVIEW 79
- Business driver 4: Management 81
- OVERVIEW 81
- Planning, and performance monitoring and reporting 82
- Transparency, lawfulness and internal control 82
- Administration and resources management 83
- Information and communication technology 83
- Annexes 88
- Annex I. Organisation chart 88
- Annex II. Estimated resource allocation per activity 2024-2026 89
- Annex III: Financial resources for 2024-2026 91
- Annex IV: Human resources – quantitative 96
- Annex V: Human resources – qualitative 101
- Annex VI. Environment management 110
- Annex VII. Building policy 114
- Annex VIII. Privileges and immunities 115
- Annex IX. Evaluations 116
- Annex X. Strategy for the organisational management and internal control systems 124
- Annex XI. Plan for grant, contribution or service-level agreements 126
- Annex XII. Strategy for cooperation with third countries and/or international organisations 131
- Annex XIII. Procurement for non-administrative activities envisaged for 2024 132
- Annex XIV. Risk factors 135
